mms ben dudley

Ben is a seasoned executive with experience gained over a 27-year career in the industry, in both the biopharma and clinical development services sectors. Ben’s deep, broad expertise spans drug development, sales and customer relationship management, operational leadership, and process optimization. He has led truly global teams and diverse delivery portfolios.

Before joining MMS, Ben served as EVP, Head of Global Project Leadership at Parexel, where he was responsible for delivering the full-service clinical project portfolio globally, across biotech and large-pharma segments. Prior roles at Parexel included key sales leadership and strategic partnership positions with large pharma customers. His impressive career also includes leadership roles at Covance and AstraZeneca, where he consistently demonstrated his ability to lead and innovate across various operational, functional, and commercial domains.

The company holds a significant place in the global CRO landscape, and I have witnessed the strength of their expertise over the years. I relish the opportunity to be part of the leadership of an organization with unique capabilities and culture as we continue the next stage of growth and delivery for our customers.
Ben Dudley
Chief Commercial Officer

Ben’s extensive industry experience, particularly in drug development and customer relationship management, equips him with the agility and effectiveness needed to help MMS continue its forward momentum. As CCO, Ben is accountable for all Commercial, Sales and Marketing functions, and strategic growth planning to continually enhance the value of MMS service offerings to our customers and ultimately patients.

Suggested For You

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium